Search research articles
Contact Us
Filters
Showing results (11-20 of 29) with videos related to
Page
of 3
Sort By:
BMJ Open
|
April 9, 2022
Incremental benefits of novel pharmaceuticals in the UK: a cross-sectional analysis of NICE technology appraisals from 2010 to 2020
Tobias B Polak, David GJ Cucchi, Jonathan J Darrow, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
May 16, 2012
Condition-specific preference-based measures: benefit or burden?
Matthijs M Versteegh, Annemieke Leunis, Carin A Uyl-de Groot, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|
August 1, 2013
Time to tweak the TTO: results from a comparison of alternative specifications of the TTO
Matthijs M Versteegh, Arthur E Attema, Mark Oppe, et al.
Health Economics
|
October 30, 2016
Are Health State Valuations from the General Public Biased? A Test of Health State Reference Dependency Using Self-assessed Health and an Efficient Discrete Choice Experiment
Marcel F Jonker, Arthur E Attema, Bas Donkers, et al.
Pharmacoeconomics
|
February 19, 2021
Methodological Challenges in the Economic Evaluation of a Gene Therapy for RPE65-Mediated Inherited Retinal Disease: The Value of Vision
Simone A Huygens, Matthijs M Versteegh, Stefan Vegter, et al.
BMC Medical Research Methodology
|
January 12, 2023
In search of a 'pan-European value set'; application for EQ-5D-3L
Ayesha Sajjad, Matthijs M Versteegh, Irene Santi, et al.
Health Economics
|
March 8, 2012
Lead time TTO: leading to better health state valuations?
Arthur E Attema, Matthijs M Versteegh, Mark Oppe, et al.
Health and Quality of Life Outcomes
|
January 24, 2015
Testing mapping algorithms of the cancer-specific EORTC QLQ-C30 onto EQ-5D in malignant mesothelioma
David T Arnold, Donna Rowen, Matthijs M Versteegh, et al.
Molecular Diagnosis & Therapy
|
April 14, 2024
Estimating the Prognostic Value of the NTRK Fusion Biomarker for Comparative Effectiveness Research in The Netherlands
Irene Santi, Heleen Vellekoop, Matthijs M Versteegh, et al.
Multiple Sclerosis and Related Disorders
|
November 9, 2023
Benefits of sphingosine-1-phosphate receptor modulators in relapsing MS estimated with a treatment sequence model
Cato E A Corsten, Simone A Huygens, Matthijs M Versteegh, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 29) with videos related to
Sort By:
Page
of 3
BMJ Open
|
April 9, 2022
Incremental benefits of novel pharmaceuticals in the UK: a cross-sectional analysis of NICE technology appraisals from 2010 to 2020
Tobias B Polak, David GJ Cucchi, Jonathan J Darrow, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
May 16, 2012
Condition-specific preference-based measures: benefit or burden?
Matthijs M Versteegh, Annemieke Leunis, Carin A Uyl-de Groot, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|
August 1, 2013
Time to tweak the TTO: results from a comparison of alternative specifications of the TTO
Matthijs M Versteegh, Arthur E Attema, Mark Oppe, et al.
Health Economics
|
October 30, 2016
Are Health State Valuations from the General Public Biased? A Test of Health State Reference Dependency Using Self-assessed Health and an Efficient Discrete Choice Experiment
Marcel F Jonker, Arthur E Attema, Bas Donkers, et al.
Pharmacoeconomics
|
February 19, 2021
Methodological Challenges in the Economic Evaluation of a Gene Therapy for RPE65-Mediated Inherited Retinal Disease: The Value of Vision
Simone A Huygens, Matthijs M Versteegh, Stefan Vegter, et al.
BMC Medical Research Methodology
|
January 12, 2023
In search of a 'pan-European value set'; application for EQ-5D-3L
Ayesha Sajjad, Matthijs M Versteegh, Irene Santi, et al.
Health Economics
|
March 8, 2012
Lead time TTO: leading to better health state valuations?
Arthur E Attema, Matthijs M Versteegh, Mark Oppe, et al.
Health and Quality of Life Outcomes
|
January 24, 2015
Testing mapping algorithms of the cancer-specific EORTC QLQ-C30 onto EQ-5D in malignant mesothelioma
David T Arnold, Donna Rowen, Matthijs M Versteegh, et al.
Molecular Diagnosis & Therapy
|
April 14, 2024
Estimating the Prognostic Value of the NTRK Fusion Biomarker for Comparative Effectiveness Research in The Netherlands
Irene Santi, Heleen Vellekoop, Matthijs M Versteegh, et al.
Multiple Sclerosis and Related Disorders
|
November 9, 2023
Benefits of sphingosine-1-phosphate receptor modulators in relapsing MS estimated with a treatment sequence model
Cato E A Corsten, Simone A Huygens, Matthijs M Versteegh, et al.
Page
of 3